Patent SG-11201805186V-A (SG)
Title: Compositions and methods for immune cell modulation in adoptive immunotherapies
Inventor: ROSEN JONATHAN
IPC: C12N5/0783
Filed: 2017-01-20
Abstract: WO 17 / 1277 29 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/127729 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: C12N 5/0783 (2010.01) A61K 35/17 (2014.01) (21) International Application Number: PCT/US2017/014408 (22) International Filing Date: 20 January 2017 (20.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/281,064 20 January 2016 (20.01.2016) US 62/336,339 13 May 2016 (13.05.2016) US (71) Applicant: FATE THERAPEUTICS, INC. [US/US]; 3535 General Atomics Court, Suite 200, San Diego, Cali- fornia 92121 (US). (72) Inventors: ROSEN, Jonathan; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). REZNER, Betsy; c/o Fate Thera- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, peutics, Inc, 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). VALAMEHR, Bahram; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). BJORDAHL, Ryan; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). PERALTA, Eigen; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). (74) Agents: NGUYEN, Thu et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, Dis- trict of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Decl arations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) [Continued on next page] (54) Title: COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE 1MMUNOTHERAPIES 4 Figure 1 (57) : Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided. 11111111111111011101111111111101011111011101110101110111110111110111111111110111111 Color by of YMO1111y .1.14z MAO) C4.44 X of ;\"daily EL. 511.0) WO 2017/127729 Al 1#11101M011010112010EMOMOHOEHOHEMOMOVOIMIE as to the applicant's entitlement to claim the priority of Published: the earlier application (Rule 4.17(iii)) — with international search report (Art. 21(3))